Phico Therapeutics Overview

  • Founded
  • 2000
Founded
  • Status
  • Private
  • Employees
  • 14
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $9.7M
Latest Deal Amount
  • Investors
  • 21

Phico Therapeutics General Information

Description

Developer of an intravenous engineered bacteriophage drug designed to treat ventilator-associated pneumonia. The company's drug uses engineered bacterial viruses combined with antibacterial small acid-soluble spore proteins to prevent the release of toxins, thereby enabling physicians to target the pneumonia bacteria and inactivate its DNA to stop it from reproducing and spreading.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Pharmaceuticals
Primary Office
  • Bertarelli Building, Bourn Hall
  • High Street, Bourn
  • Cambridgeshire CB23 2TN
  • England, United Kingdom
+44 01954 000000

Phico Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Phico Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
25. Later Stage VC 11-May-2021 $9.7M 000.00 Completed Profitable
24. Grant 19-Apr-2021 000.00 000.00 Completed Profitable
23. Later Stage VC 14-May-2019 000.00 000.00 000.00 Completed Profitable
22. Grant 01-Aug-2018 00.000 000.00 Completed Profitable
21. Later Stage VC 28-Sep-2017 00.000 000.00 000.00 Completed Profitable
20. Later Stage VC 15-Dec-2016 00.000 000.00 000.00 Completed Profitable
19. Grant 09-Mar-2015 00.000 0000 Completed Profitable
18. Later Stage VC 19-Aug-2014 00.000 0000 000.00 Completed Profitable
17. Later Stage VC 17-Dec-2013 $2.62M $20.9M 000.00 Completed Profitable
16. Later Stage VC 19-Dec-2012 $1.31M $18.3M 000.00 Completed Profitable
To view Phico Therapeutics’s complete valuation and funding history, request access »

Phico Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 0,000,000 00.000000 000.0 000.0 00 000.0 0.00
A Ordinary 000,000 00.000000 00.0 00.0 00 00.0 00.000
A Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
A Ordinary 392,156 $0.001300 $3.31 $3.31 1x $3.31 6.67%
Ordinary 714,034 $0.001300 $3.9 $3.9 1x $3.9 12.15%
To view Phico Therapeutics’s complete cap table history, request access »

Phico Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
Heather Fairhead Ph.D Founder, Chief Executive Officer & Board Member
Andrew Armour Finance Director
You’re viewing 2 of 5 executive team members. Get the full list »

Phico Therapeutics Board Members (10)

Name Representing Role Since
Anthony Martin Ph.D Phico Therapeutics Chairman 000 0000
David Beadle Phico Therapeutics Board Member 000 0000
Mark Wilcox Phico Therapeutics Board Member 000 0000
Timothy Rea Phico Therapeutics Board Member 000 0000
You’re viewing 4 of 10 board members. Get the full list »

Phico Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Phico Therapeutics Investors (21)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BGF Growth/Expansion Minority 000 0000 000000 0
CARB-X University Minority 000 0000 000000 0
24Haymarket Angel Group Minority 000 0000 000000 0
Greenwood Way Capital Angel Group Minority 000 0000 000000 0
Timothy Rea Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 21 investors. Get the full list »